๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Mutational and structural analysis of Japanese patients with mucopolysaccharidosis type II

โœ Scribed by Tomomi Kato; Zenichiro Kato; Izumi Kuratsubo; Noboru Tanaka; Tabito Ishigami; Jun-ichi Kajihara; Kazuko Sukegawa-Hayasaka; Koji Orii; Koji Isogai; Toshiyuki Fukao; Nobuyuki Shimozawa; Tadao Orii; Naomi Kondo; Yasuyuki Suzuki


Publisher
Nature Publishing Group
Year
2005
Tongue
English
Weight
356 KB
Volume
50
Category
Article
ISSN
1435-232X

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Mutational analysis of 105 mucopolysacch
โœ Litsa Karageorgos; Doug A. Brooks; Anthony Pollard; Elizabeth L. Melville; Leann ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 294 KB ๐Ÿ‘ 1 views

## Communicated by William Sly Mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome) is a lysosomal storage disorder caused by mutations in the N-acetylgalactosamine-4-sulfatase (arylsulfatase B, ARSB) gene. ARSB is a lysosomal enzyme involved in the degradation of the glycosaminoglycans

Mutational analysis of mucopolysaccharid
โœ L. Karageorgos; P. Harmatz; J. Simon; A. Pollard; P. R. Clements; D. A. Brooks; ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 121 KB ๐Ÿ‘ 1 views

## Communicated by Andreas Gal Mucopolysaccharidosis type VI (MPS VI), or Maroteaux-Lamy syndrome, is a lysosomal storage disorder caused by a deficiency of N-acetylgalactosamine-4-sulfatase (ARSB). Seven MPS VI patients were chosen for the initial clinical trial of enzyme replacement therapy. Dir

Molecular analysis of 40 Italian patient
โœ Mirella Filocamo; Gloria Bonuccelli; Fabio Corsolini; Raffaella Mazzotti; Robert ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 34 KB ๐Ÿ‘ 1 views

Mucopolysaccharidosis type II (MPS2, or Hunter syndrome), rare X-linked lysosomal storage disorder, results from deleterious mutations in the iduronate-2-sulfatase (IDS) gene. We report here the mutational analysis of a total of 40 unrelated Italian MPS II patients ranging from mild to severe phenot